{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T01:04:08Z","timestamp":1787965448033,"version":"build-2784847793"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T00:00:00Z","timestamp":1735603200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T00:00:00Z","timestamp":1735603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Fund Project of Anhui Medical University","award":["2021xkj113"],"award-info":[{"award-number":["2021xkj113"]}]},{"name":"Fund Project of Anhui Medical University","award":["2021xkj113"],"award-info":[{"award-number":["2021xkj113"]}]},{"name":"Fund Project of Anhui Medical University","award":["2021xkj113"],"award-info":[{"award-number":["2021xkj113"]}]},{"name":"Fund Project of Anhui Medical University","award":["2021xkj113"],"award-info":[{"award-number":["2021xkj113"]}]},{"name":"Fund Project of Hefei Fourth People\u2019s Hospital","award":["HFSY202109"],"award-info":[{"award-number":["HFSY202109"]}]},{"name":"Fund Project of Hefei Fourth People\u2019s Hospital","award":["HFSY202109"],"award-info":[{"award-number":["HFSY202109"]}]},{"name":"Fund Project of Hefei Fourth People\u2019s Hospital","award":["HFSY202109"],"award-info":[{"award-number":["HFSY202109"]}]},{"name":"Fund Project of Hefei Fourth People\u2019s Hospital","award":["HFSY202109"],"award-info":[{"award-number":["HFSY202109"]}]},{"name":"Hefei Seventh cycle Key Medical Specialty"},{"name":"Anhui Province Medical and Health Key Specialty Construction Project"},{"name":"National Clinical Key Specialty Construction Project of China"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"DOI":"10.1186\/s12888-024-06437-0","type":"journal-article","created":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T05:23:53Z","timestamp":1735622633000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Peripheral blood complement factors C2 and C3 as biomarkers of clinical efficacy in patients with first-episode schizophrenia after aripiprazole treatment"],"prefix":"10.1186","volume":"24","author":[{"given":"Yin","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biao","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingrong","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,31]]},"reference":[{"key":"6437_CR1","doi-asserted-by":"publisher","first-page":"104257","DOI":"10.1016\/j.nbd.2018.08.016","volume":"131","author":"FC Nucifora Jr","year":"2019","unstructured":"Nucifora FC Jr., Woznica E, Lee BJ, Cascella N, Sawa A. Treatment resistant schizophrenia: clinical, biological, and therapeutic perspectives. Neurobiol Dis. 2019;131:104257.","journal-title":"Neurobiol Dis"},{"key":"6437_CR2","doi-asserted-by":"publisher","first-page":"113771","DOI":"10.1016\/j.psychres.2021.113771","volume":"298","author":"P Gosek","year":"2021","unstructured":"Gosek P, Kotowska J, Rowinska-Garbien E, Bartczak D, Heitzman J. Treatment resistance and prolonged length of stay among schizophrenia inpatients in forensic institutions. Psychiatry Res. 2021;298:113771.","journal-title":"Psychiatry Res"},{"issue":"1","key":"6437_CR3","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41537-023-00409-1","volume":"9","author":"H Yu","year":"2023","unstructured":"Yu H, Ni P, Tian Y, Zhao L, Li M, Li X, Wei W, Wei J, Wang Q, Guo W, et al. Association of elevated levels of peripheral complement components with cortical thinning and impaired logical memory in drug-naive patients with first-episode schizophrenia. Schizophrenia (Heidelb). 2023;9(1):79.","journal-title":"Schizophrenia (Heidelb)"},{"issue":"6","key":"6437_CR4","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1093\/schbul\/sby058","volume":"44","author":"FJ Charlson","year":"2018","unstructured":"Charlson FJ, Ferrari AJ, Santomauro DF, Diminic S, Stockings E, Scott JG, McGrath JJ, Whiteford HA. Global Epidemiology and burden of Schizophrenia: findings from the global burden of Disease Study 2016. Schizophr Bull. 2018;44(6):1195\u2013203.","journal-title":"Schizophr Bull"},{"issue":"3","key":"6437_CR5","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/S2215-0366(14)00122-9","volume":"2","author":"GM Khandaker","year":"2015","unstructured":"Khandaker GM, Cousins L, Deakin J, Lennox BR, Yolken R, Jones PB. Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment. Lancet Psychiatry. 2015;2(3):258\u201370.","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"6437_CR6","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41537-024-00466-0","volume":"10","author":"HF North","year":"2024","unstructured":"North HF, Weissleder C, Bitar M, Barry G, Fullerton JM, Webster MJ, Weickert CS. RNA-sequencing suggests extracellular matrix and vasculature dysregulation could impair neurogenesis in schizophrenia cases with elevated inflammation. Schizophrenia (Heidelb). 2024;10(1):50.","journal-title":"Schizophrenia (Heidelb)"},{"key":"6437_CR7","doi-asserted-by":"crossref","unstructured":"Golam MK, Lesley C, Julia D, Belinda RL, Robert Y, Peter BJ. Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment. Lancet Psychiatry. 2015;2(3).","DOI":"10.1016\/S2215-0366(14)00122-9"},{"key":"6437_CR8","doi-asserted-by":"crossref","unstructured":"Norbert M. Inflammation in Schizophrenia: pathogenetic aspects and therapeutic considerations. Schizophr Bull. 2018;44(5).","DOI":"10.1093\/schbul\/sby024"},{"key":"6437_CR9","doi-asserted-by":"crossref","unstructured":"Jess H, Michael D, John M, James S. Modifiable risk factors for schizophrenia and autism\u2013shared risk factors impacting on brain development. Neurobiol Dis. 2012;53(0).","DOI":"10.1016\/j.nbd.2012.10.023"},{"key":"6437_CR10","doi-asserted-by":"crossref","unstructured":"Vishwajit LN, Robert HY. Neurotropic infectious agents and cognitive impairment in schizophrenia. Schizophr Bull. 2012;38(6).","DOI":"10.1093\/schbul\/sbs125"},{"key":"6437_CR11","doi-asserted-by":"crossref","unstructured":"Philip MEB, Merete RN, William N, Susanne WE, Preben OD. B M: Autoimmune diseases and severe infections as risk factors for schizophrenia: a 30-year population-based register study. Am J Psychiatry. 2011;168(12).","DOI":"10.1176\/appi.ajp.2011.11030516"},{"key":"6437_CR12","unstructured":"Kathleen S, Harry P, Elizabeth L, T-U W W, Ross JB, John H, Sabina B. What can we learn about brain donors? Use of clinical information in human postmortem brain research. Handb Clin Neurol. 2018;150(0)."},{"key":"6437_CR13","doi-asserted-by":"crossref","unstructured":"Marinos CD, Harry A, Peter JS. Complement in neurological disorders and emerging complement-targeted therapeutics. Nat Rev Neurol. 2020;16(11).","DOI":"10.1038\/s41582-020-0400-0"},{"issue":"6","key":"6437_CR14","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s00281-021-00892-7","volume":"43","author":"RB Pouw","year":"2021","unstructured":"Pouw RB, Ricklin D. Tipping the balance: intricate roles of the complement system in disease and therapy. Semin Immunopathol. 2021;43(6):757\u201371.","journal-title":"Semin Immunopathol"},{"key":"6437_CR15","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3389\/fnins.2020.00023","volume":"14","author":"J Magdalon","year":"2020","unstructured":"Magdalon J, Mansur F, Teles ESAL, de Goes VA, Reiner O, Sertie AL. Complement system in Brain Architecture and Neurodevelopmental disorders. Front Neurosci. 2020;14:23.","journal-title":"Front Neurosci"},{"issue":"1","key":"6437_CR16","doi-asserted-by":"publisher","first-page":"e05899","DOI":"10.1016\/j.heliyon.2021.e05899","volume":"7","author":"C Namatame","year":"2021","unstructured":"Namatame C, Misu T, Takai Y, Nishiyama S, Nakashima I, Fujihara K, Aoki M. CH50 as a putative biomarker of eculizumab treatment in neuromyelitis optica spectrum disorder. Heliyon. 2021;7(1):e05899.","journal-title":"Heliyon"},{"key":"6437_CR17","doi-asserted-by":"crossref","unstructured":"Yin C, Yayun X, Qingrong X, Feng S, Jun L. Peripheral complement factor-based biomarkers for patients with first-episode Schizophrenia. Neuropsychiatr Dis Treat. 2023;19(0).","DOI":"10.2147\/NDT.S420475"},{"key":"6437_CR18","doi-asserted-by":"crossref","unstructured":"Adrian P, Bryan BS. A safety evaluation of aripiprazole in the treatment of schizophrenia. Expert Opin Drug Saf. 2020;19(12).","DOI":"10.1080\/14740338.2020.1832990"},{"key":"6437_CR19","doi-asserted-by":"crossref","unstructured":"Daisy LS, Alex F, Christopher JL, Gregory DS. Beyond antipsychotics: a twenty-first century update for preclinical development of schizophrenia therapeutics. Transl Psychiatry. 2022;12(1).","DOI":"10.1038\/s41398-022-01904-2"},{"key":"6437_CR20","doi-asserted-by":"crossref","unstructured":"Jaros\u0142aw S, \u0141ukasz K, Monika R-C, El\u017cbieta \u015a, Piotr G. The effect of aripiprazole on leptin levels of patients with chronic schizophrenia and a comparison of leptin, acute phase protein, and cytokine levels with regard to body mass and body composition indexes. Endokrynol Pol. 2022;73(1).","DOI":"10.5603\/EP.a2021.0110"},{"key":"6437_CR21","doi-asserted-by":"crossref","unstructured":"Afrooz M-B, Mohammad S, Majid J-S, Manijeh M, Parvaneh R-M. Anti-inflammatory and protective effects of Aripiprazole on TNBS-Induced colitis and associated depression in rats: role of kynurenine pathway. Int Immunopharmacol. 2024;133(0).","DOI":"10.1016\/j.intimp.2024.112158"},{"key":"6437_CR22","doi-asserted-by":"crossref","unstructured":"Jaros\u0142aw S, Monika R-C, El\u017cbieta \u015a, Piotr G. Therapeutic effect of aripiprazole in chronic schizophrenia is accompanied by anti-inflammatory activity. Pharmacol Rep. 2015;67(2).","DOI":"10.1016\/j.pharep.2014.09.007"},{"key":"6437_CR23","doi-asserted-by":"publisher","first-page":"577793","DOI":"10.1016\/j.jneuroim.2021.577793","volume":"363","author":"AJ Mohd Asyraf","year":"2022","unstructured":"Mohd Asyraf AJ, Nour El Huda AR, Hanisah MN, Norsidah KZ, Norlelawati AT. Relationship of selective complement markers with schizophrenia. J Neuroimmunol. 2022;363:577793.","journal-title":"J Neuroimmunol"},{"key":"6437_CR24","doi-asserted-by":"crossref","unstructured":"Kangkang X, Jingli C, Yarui W, Yuan C, Shaoqiang H, Caihong W, Yong Z, Xueqin S, Jingliang C. Altered static and dynamic functional connectivity of habenula in first-episode, drug-na\u00efve schizophrenia patients, and their association with symptoms including hallucination and anxiety. Front Psychiatry. 2023;14(0).","DOI":"10.3389\/fpsyt.2023.1078779"},{"key":"6437_CR25","doi-asserted-by":"crossref","unstructured":"A F SRK, L A O. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2).","DOI":"10.1093\/schbul\/13.2.261"},{"key":"6437_CR26","unstructured":"Zhuoqiu Z, Hong D, Ying C, Shuiying L, Qian Z, Hua L, Lifang L, Ling L, Wenwu S. Cross-sectional survey of the relationship of symptomatology, disability and family burden among patients with schizophrenia in Sichuan, China. Shanghai Arch Psychiatry. 2014;26(1)."},{"key":"6437_CR27","unstructured":"A R: Discussion: recent developments in ascertainment and scaling of the BPRS. Psychopharmacol Bull. 1988;24(1)."},{"key":"6437_CR28","doi-asserted-by":"crossref","unstructured":"D W C B. L: Assessing psychopathology in Chinese psychiatric patients in Hong Kong using the brief Psychiatric Rating Scale. Acta Psychiatr Scand. 1993;87(1).","DOI":"10.1111\/j.1600-0447.1993.tb03327.x"},{"key":"6437_CR29","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.2147\/NDT.S374577","volume":"18","author":"M Zhao","year":"2022","unstructured":"Zhao M, Qin B, Mao Y, Wang H, Wang A, Wang C. Efficacy and safety of low-dose brexpiprazole for Acute Schizophrenia: Meta-Analysis of Randomized Placebo-controlled trials. Neuropsychiatr Dis Treat. 2022;18:1705\u201313.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"6437_CR30","unstructured":"Rikke H, Dorte H, Birgitte F, Axel S, Kaare C, Thomas MW, Merete N, Birte G. Heritability of Schizophrenia and Schizophrenia Spectrum based on the nationwide Danish twin Register. Biol Psychiatry. 83(6)."},{"key":"6437_CR31","doi-asserted-by":"crossref","unstructured":"Antti T, Heidi T, Mary C, David C, Jari T. Incidence of schizophrenia and influence of prenatal and infant exposure to viral infectious diseases. Acta Psychiatr Scand. 2021;143(6).","DOI":"10.1111\/acps.13295"},{"key":"6437_CR32","doi-asserted-by":"crossref","unstructured":"Yu C, Zhenguo Z, Fen L, Lifang W, Zheng L, Weihua Y. Associations between genotype and peripheral complement proteins in first-episode psychosis: Evidences from C3 and C4. Front Genet. 2021;12(0).","DOI":"10.3389\/fgene.2021.647246"},{"key":"6437_CR33","doi-asserted-by":"crossref","unstructured":"Jingfeng S, Xia F, Kaiyuan C, Zeman F, Handi Z. Plasma complement component 4 alterations in patients with schizophrenia before and after antipsychotic treatment. Asian J Psychiatr. 2022;73(0).","DOI":"10.1016\/j.ajp.2022.103110"},{"key":"6437_CR34","doi-asserted-by":"crossref","unstructured":"Angela G-A, Munjal MA, Andrea JT. The role of complement in synaptic pruning and neurodegeneration. Immunotargets Ther. 2021;10(0).","DOI":"10.2147\/ITT.S305420"},{"key":"6437_CR35","doi-asserted-by":"crossref","unstructured":"Karine RM, Daniel RW, Robert BS. The complement system in schizophrenia. Drug News Perspect. 2008;21(4).","DOI":"10.1358\/dnp.2008.21.4.1213349"},{"key":"6437_CR36","doi-asserted-by":"crossref","unstructured":"John DL, Liam GC, Trent MW. Complement dysregulation in the central nervous system during development and disease. Semin Immunol. 2019;45(0).","DOI":"10.1016\/j.smim.2019.101340"},{"key":"6437_CR37","doi-asserted-by":"crossref","unstructured":"Abhishek S, Ahmad AA, Uday K, Maria Elena F. Immune-mediated neuropathies: pathophysiology and management. Int J Mol Sci. 2023;24(8).","DOI":"10.3390\/ijms24087288"},{"key":"6437_CR38","doi-asserted-by":"crossref","unstructured":"S L B, M T T, E F T, M A K DB. R H Y: maternal infections and subsequent psychosis among offspring. Arch Gen Psychiatry. 2001;58(11).","DOI":"10.1001\/archpsyc.58.11.1032"},{"key":"6437_CR39","doi-asserted-by":"crossref","unstructured":"Antonino M, Fabrizio B, Giuliana M, Alessandro R, Maria Salvina S. Neutrophil-lymphocyte ratio values in Schizophrenia: a comparison between oral and long-acting antipsychotic therapies. Brain Sci. 2024;14(6).","DOI":"10.3390\/brainsci14060602"},{"key":"6437_CR40","doi-asserted-by":"crossref","unstructured":"Britta S, Irina S, Christine SF, Stefan B, Denise H-K, Kai GK. Second generation atypical antipsychotics olanzapine and aripiprazole reduce expression and secretion of inflammatory cytokines in human immune cells. J Psychiatr Res. 2018;105(0).","DOI":"10.1016\/j.jpsychires.2018.08.017"},{"key":"6437_CR41","doi-asserted-by":"crossref","unstructured":"Samantha A-H, Ra\u00fal E, Oscar M-C, Ricardo S, Yvonne F, Gabriela H-A, Jos\u00e9 Luis M-G, Enrique B-V, Gilberto P-S, Lenin P. Immunoendocrine Peripheral Effects Induced by Atypical Antipsychotics. Front Endocrinol (Lausanne). 2020;11(0).","DOI":"10.3389\/fendo.2020.00195"},{"issue":"9618","key":"6437_CR42","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","volume":"371","author":"R Kahn","year":"2008","unstructured":"Kahn R, Fleischhacker W, Boter H, Davidson M, Vergouwe Y, Keet I, Gheorghe M, Rybakowski J, Galderisi S, Libiger J, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet (London England). 2008;371(9618):1085\u201397.","journal-title":"Lancet (London England)"},{"key":"6437_CR43","doi-asserted-by":"publisher","first-page":"967941","DOI":"10.3389\/fpsyt.2022.967941","volume":"13","author":"U Zahid","year":"2022","unstructured":"Zahid U, McCutcheon R, Borgan F, Jauhar S, Pepper F, Nour M, Rogdaki M, Osugo M, Murray G, Hathway P, et al. The effect of antipsychotics on glutamate levels in the anterior cingulate cortex and clinical response: a H-MRS study in first-episode psychosis patients. Front Psychiatry. 2022;13:967941.","journal-title":"Front Psychiatry"},{"issue":"12","key":"6437_CR44","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1001\/archpsyc.60.12.1228","volume":"60","author":"O Agid","year":"2003","unstructured":"Agid O, Kapur S, Arenovich T, Zipursky R. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry. 2003;60(12):1228\u201335.","journal-title":"Arch Gen Psychiatry"},{"key":"6437_CR45","doi-asserted-by":"crossref","unstructured":"Edoardo V, Carmine B, Cecilia N, Francesca G, Annunziata S, Gaia P, Umberto B, Antonio M. Immune dyscrasia in adult growth hormone deficiency: evaluation of hemolytic complement activity (CH50) and IgG subclasses. Biomed Pharmacother. 2020;131(0).","DOI":"10.1016\/j.biopha.2020.110757"},{"key":"6437_CR46","doi-asserted-by":"crossref","unstructured":"Clare Elizabeth T, Bridget J-B, Alex C, Patrick S, Fabian B, Stephen J, Rachel S, Mark P, Andrew R, Tariq E-S et al. Quantification of human complement C2 protein using an automated turbidimetric immunoassay. Clin Chem Lab Med. 2018;56(9).","DOI":"10.1515\/cclm-2017-1068"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-024-06437-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-024-06437-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-024-06437-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T06:04:24Z","timestamp":1735625064000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-024-06437-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,31]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["6437"],"URL":"https:\/\/doi.org\/10.1186\/s12888-024-06437-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4680675\/v1","asserted-by":"object"}]},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,31]]},"assertion":[{"value":"3 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All subjects provided signed informed consent in accordance with the Declaration of Helsinki. The study was approved by the Ethics Committee of the Fourth People\u2019s Hospital of Hefei City under the registration number HFSY-IRB-PJ-CY-2022001.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}},{"value":"The authors report no conflicts of interest in this work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}],"article-number":"961"}}